PARK2 exerts a tumor suppressive function in vitro and in vivo, including retarding growth, migration, invasion, and metastasis and promotes apoptosis of NSCLC cells through inhibition of the EGFR/AKT/mTOR pathway. Here, EGFR is linked to non-small cell lung carcinoma.